false 0001719406 0001719406 2024-08-14 2024-08-14 0001719406 nxrp:CommonStockCustomMember 2024-08-14 2024-08-14 0001719406 nxrp:WarrantsToPurchaseOneShareOfCommonStockCustomMember 2024-08-14 2024-08-14
 
UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION 
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT 
PURSUANT TO SECTION 13 OR 15(d) OF THE 
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported) August 14, 2024
 
NRX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
  
001-38302
  
82-2844431
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(I.R.S. Employer
Identification No.)
 
1201 Orange Street, Suite 600
Wilmington, Delaware 19801
(Address of principal executive offices) (Zip Code)
 
(484) 254-6134
(Registrant’s telephone number, including area code)
 
N/A
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which
registered
Common Stock, par value $0.001 per  share
  
NRXP
  
The Nasdaq Stock Market LLC
Warrants to purchase one share of  Common Stock
  
NRXPW
  
The Nasdaq Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 
 
 
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On August 14, 2024, NRx Pharmaceuticals, Inc. (the “Company”) announced that Stephen Willard, the Company’s Chief Executive Officer, (“CEO”) has recommended that the Company’s shareholders would be best served by a CEO with commercial pharmaceutical experience, particularly drug launch experience, given the Company’s upcoming new drug applications for NRX-100 and NRX-101.  As a result, the Company has initiated a search for a new CEO possessing the desired qualifications.  Mr. Willard will continue to serve as the Company’s CEO while this search is initiated. 
 
Mr. Willard has indicated that his recommendation is not the result of any disagreement regarding any matter relating to the Company’s operations, policies, or practices. 
 
Item 8.01. Other Events
 
See Item 5.02 above.
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
NRX PHARMACEUTICALS, INC.
 
                      
Date: August 20, 2024
By:
/s/ Jonathan Javitt
 
Name:
Jonathan Javitt
 
Title:
Chairman of the Board of Directors
 
 
v3.24.2.u1
Document And Entity Information
Aug. 14, 2024
Document Information [Line Items]  
Entity, Registrant Name NRX PHARMACEUTICALS, INC.
Document, Type 8-K
Document, Period End Date Aug. 14, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-38302
Entity, Tax Identification Number 82-2844431
Entity, Address, Address Line One 1201 Orange Street
Entity, Address, Address Line Two Suite 600
Entity, Address, City or Town Wilmington
Entity, Address, State or Province DE
Entity, Address, Postal Zip Code 19801
City Area Code 484
Local Phone Number 254-6134
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001719406
CommonStock Custom [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock
Trading Symbol NRXP
Security Exchange Name NASDAQ
WarrantsToPurchaseOneShareOfCommonStock Custom [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants to purchase one share of  Common Stock
Trading Symbol NRXPW
Security Exchange Name NASDAQ
NRX Pharmaceuticals (NASDAQ:NRXP)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024 Haga Click aquí para más Gráficas NRX Pharmaceuticals.
NRX Pharmaceuticals (NASDAQ:NRXP)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024 Haga Click aquí para más Gráficas NRX Pharmaceuticals.